Stockscreener 앱 받기
1.216
1.71%
0.0204
시간 외 거래:
1.26
0.044
+3.62%
전일 마감가:
$1.1956
열려 있는:
$1.2
하루 거래량:
15,925
Relative Volume:
0.35
시가총액:
$3.44M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-14.37%
1개월 성능:
-30.91%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$1.19
$1.2685
1주일 범위
$1.15
$1.42
52주 변동 폭
$1.15
$2.16
Tnf Pharmaceuticals Inc Stock (TNFA) Company Profile
명칭
Tnf Pharmaceuticals Inc
전화
856-848-8698
주소
855 N. WOLFE STREET, BALTIMORE
TNFA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| TNFA | 1.216 | 3.44M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Tnf Pharmaceuticals Inc 주식(TNFA)의 최신 뉴스
TNF Pharmaceuticals Inc (TNFA) Quarterly 10-Q Report - Quartzy
TNFA Stock Plummets to 52-Week Low at $1.15 Amid Market Struggles - Investing.com UK
Adalimumab Market 2024: Industry Growth and Future Scope - openPR
Bengals WR Tee Higgins (quad) doubtful for ‘TNF’ vs. Ravens - News- Graphic
TNF Alpha Inhibitors Market Growth Drivers And Trends: Analysis And Forecast 2024-2033 - EIN News
TNF Pharmaceuticals (NASDAQ:TNFA) Stock Quotes, Forecast and News Summary - Benzinga
TNF Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Prevail Partners - Marketscreener.com
TNF Pharmaceuticals : Announces Strategic Equity Investment Priced at a Premium to Market Form 8 K - Marketscreener.com
TNF Pharmaceuticals appoints new auditor amid exit - Investing.com India
TNF Pharmaceuticals appoints new auditor amid exit By Investing.com - Investing.com South Africa
Stock Market Movers Today • Top Gainers & Losers - Benzinga
TNF Pharmaceuticals Secures Strategic Equity Investment from Prevail Partners - citybiz
TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market - BioSpace
TNF Pharmaceuticals announces investment from Prevail Partners - TipRanks
Tumor Necrosis Factor Inhibitor Drugs Market to hit USD 50 billion by 2032, says Global Market Insights Inc. - GlobeNewswire
In Crohn's Disease, Higher Early Anti-TNF Levels May Be Crucial to Treatment Success - Medscape
United States Tumor Necrosis Factor Receptor Superfamily Member 9 Market By Application - Third Eye News
Sarcopenia Market Anticipates Impressive Growth Trajectory - GlobeNewswire
TNF Pharmaceuticals sets date for 2024 annual meeting - Investing.com India
TNF Pharmaceuticals sets date for 2024 annual meeting By Investing.com - Investing.com Canada
Tumor Necrosis Factor Inhibitor Drugs Market Insights Discussed Regarding Trends and Forecast Report 2024-2033 - WhaTech
North Face Parent V.F. Corp To Improve Gradually In Next Four To Six Quarters, Analyst Upgrades Stock - Yahoo Finance
PharmaCyte Biotech, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2024 - Marketscreener.com
Tnf LLC Decreases Stock Holdings in Amazon.com, Inc. (NASDAQ:AMZN) - Defense World
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab - StockTitan
North America Autoimmune Monoclonal Antibodies Market By Application - Third Eye News
Bills QB Josh Allen (hand) cleared for TNF vs. Dolphins - News- Graphic
TNF Week 1: Ravens-Chiefs Preview, Props, Prediction - News- Graphic
TNFA stock touches 52-week low at $1.62 amid market challenges - Investing.com UK
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 - Marketscreener.com
Tnf LLC Has $2.38 Million Position in Exxon Mobil Co. (NYSE:XOM) - Defense World
North America Chronic Intestinal Inflammation Treatment Drug Market Size, Share, Forecast, [2030] - அக்னி செய்திகள்
TNF Pharmaceuticals to initiate MYMD-1 Phase II clinical trials - Yahoo Finance
TNF Pharmaceuticals advances MYMD-1 trials for inflammation - Investing.com
TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline - StockTitan
Eleven option delistings on August 19th - TipRanks
TNF Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
TNF Pharmaceuticals, Inc. announced that it expects to receive $14 million in funding from PharmaCyte Biotech, Inc. - Marketscreener.com
Tumor Necrosis Factor Inhibitor Drugs Market: An Extensive Analysis Predicts Significant Future Growth - openPR
Tumor Necrosis Factor Inhibitor Drugs Market Size Report, 2032 - Global Market Insights
Adalimumab Biosimilar Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic
Forward Therapeutics discovers TNF-α production inhibitors - BioWorld Online
TNF Pharmaceuticals expands share count in strategic move - Investing.com India
MyMD Pharmaceuticals Rebrands as TNF Pharmaceuticals - TipRanks
TNF Pharmaceuticals debuts new ticker symbol TNFA - Investing.com
TNF Pharmaceuticals debuts new ticker symbol TNFA By Investing.com - Investing.com Nigeria
TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today - Business Wire
Tnf Pharmaceuticals Inc (TNFA) 재무 분석
Tnf Pharmaceuticals Inc (TNFA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):